Strs Ohio held its position in shares of Insys Therapeutics Inc. (NASDAQ:INSY) during the second quarter, Holdings Channel reports. The fund owned 125,000 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Strs Ohio’s holdings in Insys Therapeutics were worth $1,617,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Scopia Capital Management LP raised its position in shares of Insys Therapeutics by 53.0% in the first quarter. Scopia Capital Management LP now owns 8,912,072 shares of the specialty pharmaceutical company’s stock worth $142,504,000 after buying an additional 3,087,987 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of Insys Therapeutics during the first quarter worth about $4,493,000. Credit Agricole S A increased its stake in shares of Insys Therapeutics by 688.0% in the first quarter. Credit Agricole S A now owns 192,000 shares of the specialty pharmaceutical company’s stock worth $3,070,000 after buying an additional 167,634 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Insys Therapeutics by 50.9% in the first quarter. Adage Capital Partners GP L.L.C. now owns 400,000 shares of the specialty pharmaceutical company’s stock worth $6,396,000 after buying an additional 135,000 shares during the last quarter. Finally, A.R.T. Advisors LLC increased its stake in shares of Insys Therapeutics by 980.4% in the first quarter. A.R.T. Advisors LLC now owns 105,461 shares of the specialty pharmaceutical company’s stock worth $1,686,000 after buying an additional 95,700 shares during the last quarter. Hedge funds and other institutional investors own 47.36% of the company’s stock.
Shares of Insys Therapeutics Inc. (NASDAQ:INSY) traded up 3.18% during midday trading on Monday, reaching $12.67. 360,078 shares of the company were exchanged. The company has a 50 day moving average price of $13.89 and a 200-day moving average price of $14.91. The stock has a market capitalization of $907.11 million, a P/E ratio of 19.08 and a beta of 1.49. Insys Therapeutics Inc. has a 12-month low of $11.45 and a 12-month high of $33.88.
Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.01. The firm had revenue of $67.10 million for the quarter, compared to the consensus estimate of $66.90 million. Insys Therapeutics had a net margin of 16.03% and a return on equity of 20.08%. The company’s revenue for the quarter was down 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.21 earnings per share. On average, analysts forecast that Insys Therapeutics Inc. will post $0.35 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on INSY. Zacks Investment Research downgraded shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Jefferies Group reissued a “buy” rating and issued a $22.00 price target (up from $17.00) on shares of Insys Therapeutics in a report on Thursday, August 4th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $28.00 price target on shares of Insys Therapeutics in a report on Thursday, August 25th. Royal Bank Of Canada lowered their price target on shares of Insys Therapeutics from $32.00 to $26.00 and set an “outperform” rating on the stock in a report on Thursday, September 22nd. Finally, RBC Capital Markets reissued an “outperform” rating and issued a $26.00 price target (down from $32.00) on shares of Insys Therapeutics in a report on Friday, September 23rd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.43.
In other news, major shareholder John N. Kapoor Trust Dated Sept purchased 5,700 shares of the business’s stock in a transaction on Friday, August 12th. The stock was acquired at an average cost of $18.57 per share, for a total transaction of $105,849.00. Following the purchase, the insider now directly owns 31,982 shares in the company, valued at approximately $593,905.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Theodore H. Stanley sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $18.02, for a total value of $270,300.00. Following the sale, the director now owns 17,000 shares of the company’s stock, valued at $306,340. The disclosure for this sale can be found here. Company insiders own 69.20% of the company’s stock.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics Inc. (NASDAQ:INSY).
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.